Pharmacologically induced or siRNA-induced inhibition of FASN in breast cancer cells results in major changes in the synthesis of phospholipids that, in turn, impair the proper localization of HER2 to the cell membrane [19]. This evidence concerns the gene FASN and breast carcinoma.